ACHIEVE LIFE SCIENCES, INC.
About ACHIEVE LIFE SCIENCES, INC.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2019
- $0
- Net income
- -$54.6M
- Total assets
- $41.8M
- Market cap
- $526.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Net income
- -$54.6M
- EPS (basic)
- $-1.25
- EPS (diluted)
- $-1.25
Balance sheet
- Total assets
- $41.8M
- Current assets
- $39.9M
- Total liabilities
- $20.3M
- Current liabilities
- $9.1M
- Shareholders’ equity
- $21.5M
Cash flow
- Operating cash flow
- -$49.5M
- Investing cash flow
- $6.1M
- Financing cash flow
- $51.5M
- Net cash flow
- $8.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $526.6M
- EPS (diluted)
- $-1.25
- Shares outstanding
- 96.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 12, 1995
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $54.6M in FY2019.
- Trading 9% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ACHIEVE LIFE SCIENCES, INC..
Write a review
News about ACHIEVE LIFE SCIENCES, INC.
News & sentiment via Polygon.io
